Charles Schwab Investment Management Inc. Sells 29,708 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Charles Schwab Investment Management Inc. decreased its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 8.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 308,609 shares of the company’s stock after selling 29,708 shares during the period. Charles Schwab Investment Management Inc.’s holdings in 4D Molecular Therapeutics were worth $1,719,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Proficio Capital Partners LLC grew its stake in 4D Molecular Therapeutics by 100.0% in the fourth quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company’s stock worth $111,000 after purchasing an additional 10,000 shares during the period. Rhumbline Advisers boosted its holdings in shares of 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after buying an additional 3,675 shares in the last quarter. Peapod Lane Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth about $806,000. Marquette Asset Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 4th quarter worth about $116,000. Finally, Barclays PLC lifted its position in 4D Molecular Therapeutics by 141.0% during the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after acquiring an additional 67,202 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

FDMT has been the topic of a number of recent research reports. Royal Bank of Canada cut their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, March 22nd. Bank of America lowered their price objective on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, March 10th. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $30.63.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT opened at $3.63 on Friday. 4D Molecular Therapeutics, Inc. has a one year low of $3.45 and a one year high of $31.87. The stock has a 50-day moving average of $4.58 and a 200 day moving average of $7.03. The company has a market capitalization of $168.08 million, a price-to-earnings ratio of -1.27 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). On average, equities analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.